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Shod-term effects of recombinant human growth hormone in CAPD
patients. Protein and calorie malnutrition is common in chronic dialysis
patients. Several interventions have been proposed to prevent and/or to
treat malnutrition. Recombinant human growth hormone (rhGH) is a
drug with anabolic properties and has been used in several catabolic
conditions, such as patients with severe burns as well as in pediatric
patients with chronic renal failure. In this study, we evaluated the short-
term effects and safety of rhGH on urea kinetics and commonly measured
biochemical parameters in 10 stable adult continuous ambulatory perito-
neal dialysis (CAPD) patients. The design of the study was prospective,
cross-over with the patients serving as their own controls. There were
three study periods: baseline (PreGH), treatment (Tx), and follow-up
(PostGH). During the seven day Tx period, patients self-administered 5
mg/day s.c of rhGH. During this time, there was a significant decrease in
blood urea nitrogen (BUN) (54 15 to 40 12 mg/dl), as well as in the
combined dialysate and urine urea nitrogen excretion rate (5.69 1.86 to
4.04 1.13 g/day), and protein catabolic rate (0.82 0.13 to 0.67 0.09
g/kg/day), (aliP <0.001). Serum phosphorus (4.8 1.6 to 4.4 1.8 mg/dl)
and potassium (4.0 0.4 to 3.6 0.2 mEq/liter) levels also showed a small
but statistically significant decrease, in conjunction with a statistically
significant increase in serum creatinine levels (12.2 5.7 to 12.9 5.7
mg/dl). Dietary protein intake, determined by dietary recall, did not
change during the study (66.1 20,5 vs. 75.8 22.1 grams/day). Serum
glucose (155 98 to 213 129 mg/dl) and insulin-like growth factor 1
(193 74 to 662 261 ng/ml) levels increased significantly with rhGH
treatment. All laboratory values returned to baseline by the end of the
PostGH period. No changes were noted in dialysate protein losses, daily
creatinine excretion, serum transferrin, or prealbumin levels. No clinically
evident adverse side effects were noted. We conclude that short-term
administration of rhGH to stable CAPD patients is associated with a net
decrease in total urea nitrogen appearance, evidenced by a decrease in
concentrations of BUN and daily urea nitrogen excretion, and is consistent
with the anabolic effects of rhGH. Long-term studies are needed to define
the steady-state effects of rhGH in chronic dialysis patients.
Protein and calorie malnutrition is common in chronic dialysis
patients and has been shown to be associated with increased
mortality and morbidity in this population [1—5]. Several indices of
malnutrition have been identified and include low serum albumin
and cholesterol concentrations [6, 7], low insulin-like growth
factor-i (IGF-1) [8], transferrin and prealbumin concentrations
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[9—il], abnormal amino acid profiles [12], low percentage of ideal
body weight, and reduction in anthropometric measurements
[13, 14].
Multiple factors can lead to malnutrition in the uremic patient.
These include: anorexia and decreased nutrient intake [15—17],
hormonal derangements such as insulin resistance [18] and excess
parathyroid hormone levels [19], metabolic acidosis contributing
to increased catabolism [20, 21], frequent hospitalizations [22],
multiple medications and the socio-economic status of the patient
[23]. Dialysis-related factors, such as the use of acetate [24],
inadequate dialysis [25, 26], and the use of bioincompatible mem-
branes [27, 28], may also have an impact on the nutritional status
of this patient population.
Many interventions have been proposed to prevent or treat
malnutrition. Among these are optimal dialysis prescriptions [29],
biocompatibility of hemodialysis membranes and peritoneal dial-
ysis solutions, use of bicarbonate and volumetric control in hemo-
dialysis patients, nutritional counseling [30, 31], and intradialytic
parenteral and enteral nutritional supplements [32—35]. Several
pharmacological agents such as antiemetics and anabolic steroids
have also been used to improve the nutritional status of patients
[23]. More recently, recombinant human growth hormone (rhGH)
[36, 37] and recombinant human insulin-like growth factor-i
(rhIGF-i) [38, 39] have been proposed for the treatment of
malnutrition. Our aim in this study was to evaluate the short-term
effects of rhGH on urea appearance and to document its clinical
safety in CAPD patients.
rhGH is a drug with anabolic properties that can lead to
enhanced protein synthesis and decreased protein degradation
[40], increased food conversion ratio [41], increased fat mobiliza-
tion, and increased oxygen consumption [42]. It has been em-
ployed in catabolic states such as severe bums [43, 44], sepsis [45],
and corticosteroid administration [46] to improve the nitrogen
balance of the patients and enhance recovery. Other studies have
investigated the use of rhGH in uremic patients, demonstrating
decreased urea generation and protein catabolic rate in chronic
hemodialysis patients [36] and an increase in growth velocity and
weight gain in uremic pediatric patients [47, 48]. More recently,
improved nutritional indices were observed in chronic hemodial-
ysis (CHD) patients during concomitant use of growth hormone
and intradialytic parenteral nutrition [37]. However, the effective-
ness of growth hormone on nutritional indices in CAPD patients
has not been reported. Such patients are ideal candidates for this
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Pre-GH period
Treatment Period*
. Follow-up period
Clinic visits
* 5 mg of rHuGH/day s.c.
study since urea appearance can be quantitated accurately, and
because of the reported 40% incidence of moderate to severe
malnutrition in these patients [49].
Methods
Patient characteristics
Seven male and three female patients participated in the study.
Their mean age was 46 11.3 years (range 32 to 63) and their
mean time on peritoneal dialysis was 24 12.9 months (range 4
to 46). The causes of ESRD were: chronic glomerulonephritis (5),
hypertension (3), insulin dependent diabetes mellitus (1), and
systemic lupus erythematosus (1). All patients performed four
exchanges per day with 2 liter exchange bags of varying glucose
concentrations to achieve their dry weight. No changes were made
in patients' medications or dialysis prescriptions throughout the
study period. The participating patients were not malnourished
and their baseline serum albumin concentration was 3.8 0.4
g/dl. The study protocol was approved by the Institutional Review
Board of Vanderbilt University and written informed consent was
obtained from all patients.
Study design
The study was a prospective cross-over design with patients
serving as their own control. The study consisted of three periods:
baseline (PreGH), treatment (Tx), and follow-up (PostGH).
Patients were seen in the clinic for a total of eight visits (Fig. 1).
During the PreGH period, the patients were seen during three
clinic visits, at days 1, 4 and 8 of the study. They were instructed
on a stable diet, as well as self-administration of medication
subcutaneously. Blood and dialysate samples were obtained for
baseline values, as described below. The first rhGH was adminis-
trated on day 8 and daily during the subsequent six days (days 9
through 14); during that time the patients self-administered daily
injections of rhGH [5 mg, s.c. (Eli Lilly and Co., Indianapolis,
Indiana, USA)I. During the Tx period, patients were seen twice,
on days 10 and 12 for blood and dialysate sampling. During the
PostGH period, patients were seen three times on days 16, 19, and
28, the last day of the study period.
At each clinic visit blood samples were obtained for blood urea
nitrogen (BUN), creatinine, sodium, potassium, chloride, glucose,
total protein, albumin, bicarbonate (tCO2), phosphorus, complete
blood count, transferrin, prealbumin, insulin-like growth factor-i
(IGF-1), growth hormone (GH), and insulin-like growth factor
binding protein 3 (IGFBP-3), one of the six binding proteins
shown to correlate best with rhGH administration. Aliquots of
dialysate were obtained from the drain bags of each of the four
exchanges done the day previous to the clinic visit by collecting the
dialysate into a 4 liter graduated cylinder following each exchange
and then withdrawing a sample from the cylinder into a syringe.
The patients were also instructed in recording the volume of each
bag of drained dialysate. These samples were then analyzed for urea,
creatinine, and total protein. Twenty-four hour urine collections
from the day prior to the clinic visits were obtained from the
patients if their total urine volumes exceeded 200 mi/day. These
samples were also analyzed for urea, creatinine, and total protein.
Blood and dialysate chemistries
BUN, creatinine, glucose, total protein, albumin, transferrin,
sodium, potassium, chloride and phosphorus levels were mea-
sured by standard laboratory techniques. IGF-1 assays were
performed by radioimmunoassay technique following extraction
by acid-ethanol method (Nichols Institute Diagnostics, San Juan
Capistrano, California, USA). GH and IGFBP-3 assays were also
performed by specific radioimmunoassay techniques (Nichols
Institute Diagnostics). Prealbumin was measured by nephelomet-
nc assay (Behring BN 100 Nephelometer).
Urea kinetics
Dialysate urea concentrations, dialysate protein concentrations,
and protein catabolic rates were calculated by equations derived
by Teehan, Brown, and Schleifer [50], with slight modifications.
The daily dialysate urea nitrogen (DDUN) was calculated using
Equation 1:
(V1 x DUN1) + (V2 x DUN2) + (V3 x DUN3) + (V4
x DUN4) = DDUN (g)/24 hours (Eq. 1)
where V corresponds to the dialysate drainage volume (liters) of
the specific exchange and DUN correspond to dialysate urea
nitrogen (g/liter) of the same exchange, respectively and the
subscripts correspond to the number of the exchange done over 24
hours. Net urea nitrogen excretion (NUNE) was calculated as the
sum of DDUN and urine urea nitrogen (UUN) and the total urea
nitrogen appearance (TUNA) was calculated as the sum of
dialysate and urine urea nitrogen as well as total body urea
nitrogen content (BUN x Urea Volume of Distribution).
The daily dialysate protein (DDP) was calculated in a similar
way as Equation 1, using the measurement of total protein in each
dialysate sample.
Protein catabolic rate (PCR) was calculated according to
Equation 2,
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Fig. 1. The design of the study. Arrows depict the
clinic days. Five milligrams of rhGI-I are admin-
istered every day during the treatment period.
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Table 1. Effect of rhGH on biochemical indices during different study
periods
Baseline Treatment PostGI-1
BUN mg/d! 54 15 40 128 55 15"
Creatinine mgldl
Potassium mEqiliter
12.2 5.7
4.0 0.4
12.9 5.7"
3.6 0.2"
12.0 5.1
4.0 0.4"
Phosphorus mgldl
Glucose mgldl
4.8 1.6
155 98
4.4 1.8"
213 129"
4.7 1.9
166 83"
Albumin gld! 3.75 0.44 3.55 0.43" 3.62 0.42
Hematocrit 34.5 4.4 34.9 4.6 34.9 4.2
Data are mean so.
"p < 0.05 vs. Baseline
P < 0.05 vs. Treatment
{(DDUN + UUN + AAN + NUN)6.25 + DDP}tweight (kg)
= PCR (g/kg/day) (Eq. 2)
where UUN, AAN, and NUN, respectively, correspond to urine
urea nitrogen, dialysate amino acid nitrogen, and non-urea nitro-
gen (in urine, dialysate, and stool) over 24 hours. UUN was
derived from the measurement of urine values in patients with
urine outputs. Constant values, as reported by Teehan, Brown,
and Schleifer [50], were used for AAN (0.51 g/day) and NUN
(0.031 g/kg/day), but daily dialysate protein was measured. To
convert urea nitrogen to protein, a conversion factor of 6.25 (g of
protein per g of nitrogen) was used [501.
Diet records were obtained during one visit at each study period
by the renal dietitian and food composition was calculated using a
commercially available computer software (Nutritionist Ill®, N-
Squared Computing, Salem, Oregon, USA) to calculate daily
protein and calorie intakes.
Statistical analysis
A repeated measure analysis of variance was used to compare
the results within each of the three separate study periods. If no
difference was detected within a period, the same analysis was
performed to compare the means of the three periods. If there
was overall statistical significance across the three periods, a
paired t-test was then used to compare specific periods. A P value
< 0.05 was considered as statistically significant. SAS statistical
software package (SAS Institute, Cary, North Carolina, USA) was
used for all analyses. Results are presented as mean SD, unless
otherwise stated.
Results
There were no statistically significant differences between the
three PreGH measurements or the two Tx measurements for any
of the variables. Thus, the mean of the three PreGH measure-
ments and the mean of the two Tx measurements were used in the
subsequent analysis. Preliminary statistical analysis of data from
the PostGH period (days 16, 19, and 28) suggested that the rhGH
effect was not completely dissipated by the day 16 measurement
(that is, 2 days after the last dose of rhGH) for some patients.
Thus, this measurement was not used in the subsequent analysis.
There were no significant statistical differences between the
measurements of days 19 and 28; thus, these were averaged for
the PostGH period. The results of the means of the three study
periods are shown in Tables 1 through 3.
As can be seen in Table 1, BUN decreased from a baseline of
Table 2. Effect of rhGH on urea kinetics and creatinine excretion
during different study periods
Baseline Treatment PostGH
Dialysate urea nitrogen 4.53 1.23 3.44 1.098 4.16 1.22""
excretion giday
Net urea nitrogen 5.69 1.86 4.04 1.138 5.19 2.078t
excretion giday
Total urea nitrogen 29.58 11.04 21.36 8.138 29.26 11.13"
appearance giday
Dialysate total protein 7.45 2.32 6.97 2.92 7.52 2.51
giday
Protein catabolic rate 0.82 0.13 0,67 0.09" 0.77 0.14""
glkglday
Creatinine excretion 1.32 0.46 1.31 0.44 1.30 0.51
giday
Data are mean sli
P < 0.05 vs. Baseline
"P C 0.05 vs. Treatment
Table 3. Effect of rhGH on several nutritional indices during different
study periods
Baseline Treatment PostGH
Transferrin mg/dl 291 83 285 59 286 54
Prealbumin mgldl 42 9 40 11 40 10
LGF-1 ng/ml 193 74 662 2618 233 102"
Growth hormone nglm! 2.62 2.14 11.2 13.7 1.16 0.71
IGFBP-3 pg/mI 4.33 1.35 6.23 1.648 4.73 1.66"
Data are mean 5D.
U P C 0.05 vs. Baseline
'P C 0.05 vs. Treatment
54 15 mg!dl to 40 12 mg/dl during growth hormone
administration. This change was highly significant (P < 0.0001).
During the treatment period, serum phosphorus decreased from a
baseline of 4.8 1.6 mg/dl to 4.4 1.8 mg/dl (P C 0.05) and
serum potassium from 4.0 0.4 mflq/liter to 3.6 0.2 mEq/liter
(P < 0.001). In conjunction with these changes, a small but
statistically significant increase in serum creatinine levels (12.2
5.7 mg/dl to 12.9 5.7 mg/dl, P C 0.05) was noted. Although
small, a significant drop was also noted in the albumin levels from
3.75 0.44 g/dl at baseline to 3.55 0.43 g/dl during rhGH
treatment (P < 0.01). Postprandial glucose levels increased
significantly with growth hormone administration (155 98 mg/dl
to 213 129 mg/dl, P C 0.05), although this change was not
associated with any clinical side effects. All of these laboratory
values returned to baseline at the end of the follow-up period, and
there were no statistically significant differences between PostGH
and PreGH periods for any of the parameters in Table 1.
Hematocrit levels remained stable during all the study periods
(34.5 4.4 vs. 34.9 4.6, for PreGH and Tx periods, respectively)
and the weights of the patients did not change with rhGH
treatment (78.1 18.8 kg vs. 78.0 19.1 kg). Sodium, chloride,
and total CO2 values were not affected with rhGH treatment (all
P> 0.5, data not shown).
Table 2 depicts the changes in daily dialysate urea nitrogen
excretion (DDUN), net urea nitrogen excretion (NUNE), total
urea nitrogen appearance (TUNA), and protein catabolic rate
(PCR) during the three study periods. DDUN decreased from
4.53 1.23 g/day to 3.44 1.09 g/day and NUNE decreased from
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5.69 1.86 g/day to 4.04 1.13 g/day, (all P < 0.001). Further-
more, since BUN concentration also dropped significantly during
the Tx period (—14.4 5.2 mg/dl), the decrease in total urea
nitrogen appearance can be calculated by adding the change in
total body urea nitrogen content [(Pre-BUN — TxBUN) X Urea
Volume of Distribution] to the change in dialysate and urine urea
nitrogen. This results in approximately a 30% change of total urea
nitrogen appearance, from 29.59 11.04 g/day to 21.36 8.13
glday during growth hormone treatment, again a highly statisti-
cally significant change (P < 0.001). Protein catabolic rate de-
creased from 0.82 0.13 g/kglday to 0.67 0.09 g!kg/day (P <
0.001). Although all urea kinetic parameters trended to baseline
levels during the PostGH period, mean PostGH values of daily
dialysate urea nitrogen excretion (as well as net urea nitrogen
excretion and protein catabolic rate derived from it) were still
statistically significantly less than baseline values (Table 2). How-
ever, there was no statistically significant difference in dialysate
protein losses between the PreGH period and Tx period (7.45
2.32 glday vs. 6.97 2.92 g/day, P> 0.25), and daily creatinine
excretion was also stable during the three study periods (P >
0.25). Daily protein intakes, estimated by 24 hour dietary recall
and diet diary methods were not different between PreGH and Tx
periods (66.1 20.5 g/day vs. 75.8 22.1 g/day, respectively, P>
0.25). Similarly, daily intakes of calories, phosphorus, and potas-
sium were not different between study periods (data not shown, all
P> 0.25).
Table 3 shows the results for transferrin and prealbumin, as well
as serum IGF-1, GH, and IGFBP-3. Neither transferrin nor
prealbumin concentrations changed during the treatment. On the
other hand, serum IGF-1 and IGFBP-3 levels increased signifi-
cantly with treatment (P < 0.001). Although there was a large
increase in the average serum GH levels (from 2.62 2.14 ng/ml
to 11.2 13.7 ng/ml), this difference was not statistically signifi-
cant (0.05 < P < 0.10) because of the large variability between
patients.
Discussion
The results of our study reveal that short-term administration of
rhGH induces a significant decrease in urea appearance rate in
chronic stable CAPD patients. This is suggestive of a favorable
effect on protein turnover due to either increased anabolism or
decreased catabolism of dietary or body proteins. A net anabolic
effect is further supported by the observation of a statistically
significant decrease in phosphorus and potassium levels, associ-
ated with a small but statistically significant increase in serum
creatinine levels, while creatinine excretion remained unchanged.
Phosphorus and potassium are essential components of muscle
cells and serum creatinine level is a reflection of total body
creatine or muscle content [51,52]. Taken together, these changes
are suggestive of a modest increase in muscle mass (although its
occurrence in one week is surprising) or, less likely, a change in
the metabolism of creatinine.
These findings are consistent with previously demonstrated
effects of rhGH in catabolic patients with normal renal function,
as well as in uremics [43]. Wilmore and associates have observed
improved nitrogen balance with administration of rhGH in pa-
tients with extensive burns but otherwise normal renal function
over a wide range of nutrient intake [53, 54]; similarly, we have
recently demonstrated that long-term rhGH administration to
chronic malnourished hemodialysis patients along with intradia-
lytic parenteral nutrition resulted in improved nitrogen balance
and albumin concentration [37]. The present study extends these
findings to the administration of rhGH for a short-term period to
chronic stable CAPD patients.
It is important to note that these results assume that the
patients maintained a stable daily protein intake. Although the
patients were not in a 24 hour supervised setting (such as a clinical
research center), dietary recall did not indicate any significant
change in appetite or dietary intake during any of the three
separate study periods. In addition, most of the effects observed
with rhGH treatment returned to baseline within two weeks
following the discontinuation of rhGH administration. This fur-
ther suggests that the decrease in total urea nitrogen appearance
noted above was related to the anabolic effects of rhGH therapy,
rather than to a change in dietary intake.
Although the effectiveness of rhGH on growth in uremic and
kidney transplanted pediatric patients has been clearly defined
[47, 55], the use of rhGH in end-stage renal disease (ESRD)
patients as a component of nutritional support needs further
validation. Studies have shown that growth hormone levels in
uremic patients are either normal or slightly increased, probably
due to decreased metabolic and renal clearances [56]. In contrast,
uremic rats were shown to have decreased growth hormone
receptor and IGF-1 receptor expressions [57], consistent with
growth hormone resistance at the cellular levels in uremia. This
impaired growth hormone bioactivity has provided the rationale
for the administration rhGH in pharmacological doses as a
nutritional therapy in malnourished ESRD patients. Additionally,
animal studies have revealed an improved food conversion ratio
following rhGH administration to uremic rats, a major abnormal-
ity in uremic states [41, 58].
The mechanism(s) by which rhGH mediates its anabolic effects
is not well-defined at present. It has been demonstrated that these
effects are, at least in part, related to the induction of IGF-1
production, which has anabolic properties [59]. On the other
hand, recent studies have failed to demonstrate similar responses
in protein metabolism with direct administration of recombinant
human IGF-1 (rhIGF-1) alone, when compared to administration
of rhGH alone, even when similar serum IGF-1 levels were
achieved [601. This suggests that the anabolic effect of rhGH
extends beyond its impact on IGF-1 levels. In our study, we found
no statistically significant correlation between any of the urea
kinetic parameters and the total or normalized (to body weight)
rhGH dose, IGF-1, or IGFBP-3 levels. On the whole, these
findings suggest that the effects of rhGH on urea kinetics are
mediated through several mechanisms, rather than solely via an
increase in IGF-1 levels. Recently, Mauras, Horber, and Hay-
mond have also proposed that while administration of exogenous
IGF-1 decreases protein catabolism, rhGH has additional ana-
bolic properties independent of IGF-1 [60].
The investigation of the safety of short-term rhGH administra-
tion in CAPD patients was another aim of our study. During the
entire study period we noted no adverse clinical side effects. In
one insulin dependent patient, glucose control became more
brittle, and required increases in his insulin dosages. In this
patient, glucose values and insulin requirement returned to
baseline following discontinuation of the drug. However, the
other nine patients did not have a significant change in their
glucose levels (135 78 mgldl PreGH vs. 179 75 mgldl Tx
period, P = NS). None of the patients showed any sign of
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increased intracranial pressure, another potential side effect of
rhGH administration recently noted in children [61]. On the other
hand, serum albumin levels showed a small, but statistically
significant, decrease during rhGH treatment and returned to
baseline following discontinuation of the drug. The explanation
for this observation is not clear at present, although the fluid
retaining properties of rhGH [44], a change in amino acid
metabolism, or a direct effect of rhGH on albumin synthesis, may
be potential explanations. Nevertheless, the side effect profile of
rhGH in ESRD patients appears to be better than those noted
with IGF-1 therapy [62].
In this short-term study no changes in plasma levels of trans-
ferrin and prealbumin were noted during the rhGH treatment.
Although both parameters have been proposed as early markers
of nutritional status of dialysis patients [23], it is probable that a
seven day treatment period was insufficient to see any effect on
these indices, particularly in the patients participating in the study,
none of whom had indices commonly associated with malnutri-
tion. rhGH treatment also had no effect on dialysate protein
losses, suggesting that the properties of the peritoneum are not
affected with pharmacological doses of rhGH.
In conclusion, our study has shown that short-term rhGH
therapy induces a net anabolic effect in CAPD patients. Long-
term clinical studies of malnourished patients are needed to
define the steady-state effects of rhGH administration on nutri-
tional indices of chronic dialysis patients.
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